BridgeBio Pharma (BBIO) Enterprise Value (2019 - 2025)
Historic Enterprise Value for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$635.6 million.
- BridgeBio Pharma's Enterprise Value fell 6097.94% to -$635.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$635.6 million, marking a year-over-year decrease of 6097.94%. This contributed to the annual value of -$671.0 million for FY2024, which is 5837.76% down from last year.
- As of Q3 2025, BridgeBio Pharma's Enterprise Value stood at -$635.6 million, which was down 6097.94% from -$747.0 million recorded in Q2 2025.
- BridgeBio Pharma's Enterprise Value's 5-year high stood at -$340.9 million during Q2 2023, with a 5-year trough of -$917.8 million in Q1 2021.
- Over the past 5 years, BridgeBio Pharma's median Enterprise Value value was -$536.3 million (recorded in 2024), while the average stood at -$566.2 million.
- Per our database at Business Quant, BridgeBio Pharma's Enterprise Value soared by 4961.57% in 2023 and then crashed by 6097.94% in 2025.
- Quarter analysis of 5 years shows BridgeBio Pharma's Enterprise Value stood at -$390.5 million in 2021, then fell by 3.28% to -$403.3 million in 2022, then dropped by 5.03% to -$423.6 million in 2023, then crashed by 58.38% to -$671.0 million in 2024, then increased by 5.27% to -$635.6 million in 2025.
- Its Enterprise Value was -$635.6 million in Q3 2025, compared to -$747.0 million in Q2 2025 and -$530.6 million in Q1 2025.